770 results on '"Oka, Mikio"'
Search Results
2. Automated immunoassay of serum NY-ESO-1 and XAGE1 antibodies for predicting clinical benefit with immune checkpoint inhibitor (ICI) in advanced non-small cell lung cancer
3. Immune checkpoint therapy and response biomarkers in non-small-cell lung cancer: Serum NY-ESO-1 and XAGE1 antibody as predictive and monitoring markers
4. Inhibition of pancreatic cancer-cell growth and metastasis in vivo by a pyrazole compound characterized as a cell-migration inhibitor by an in vitro chemotaxis assay
5. A novel automated immunoassay for serum NY-ESO-1 and XAGE1 antibodies in combinatory prediction of response to anti-programmed cell death-1 therapy in non-small-cell lung cancer
6. Depletion of central memory CD8+ T cells might impede the antitumor therapeutic effect of Mogamulizumab
7. Serum Antibody Against NY-ESO-1 and XAGE1 Antigens Potentially Predicts Clinical Responses to Anti–Programmed Cell Death-1 Therapy in NSCLC
8. Clinical Reevaluation of the QuantiFERON TB-2G Test as a Diagnostic Method for Differentiating Active Tuberculosis from Nontuberculous Mycobacteriosis
9. Integrated analysis of phase 1a and 1b randomized controlled trials; Treg-targeted cancer immunotherapy with the humanized anti-CCR4 antibody, KW-0761, for advanced solid tumors
10. Beneficial effects of Galectin-9 on allergen-specific sublingual immunotherapy in a Dermatophagoides farinae-induced mouse model of chronic asthma
11. Data from Survival of Lung Adenocarcinoma Patients Predicted from Expression of PD-L1, Galectin-9, and XAGE1 (GAGED2a) on Tumor Cells and Tumor-Infiltrating T Cells
12. Supplementary Figures S1 through S6 from Survival of Lung Adenocarcinoma Patients Predicted from Expression of PD-L1, Galectin-9, and XAGE1 (GAGED2a) on Tumor Cells and Tumor-Infiltrating T Cells
13. Supplementary Tables S1 through S9 from Survival of Lung Adenocarcinoma Patients Predicted from Expression of PD-L1, Galectin-9, and XAGE1 (GAGED2a) on Tumor Cells and Tumor-Infiltrating T Cells
14. Supplementary Figure 5 from Prolongation of Overall Survival in Advanced Lung Adenocarcinoma Patients with the XAGE1 (GAGED2a) Antibody
15. Supplementary Figure 2 from Prolongation of Overall Survival in Advanced Lung Adenocarcinoma Patients with the XAGE1 (GAGED2a) Antibody
16. Supplementary Figure 6 from Prolongation of Overall Survival in Advanced Lung Adenocarcinoma Patients with the XAGE1 (GAGED2a) Antibody
17. Supplementary Figure Legend from Prolongation of Overall Survival in Advanced Lung Adenocarcinoma Patients with the XAGE1 (GAGED2a) Antibody
18. Supplementary Figure 1 from Prolongation of Overall Survival in Advanced Lung Adenocarcinoma Patients with the XAGE1 (GAGED2a) Antibody
19. Supplementary Figure 3 from Phase Ia Study of FoxP3+ CD4 Treg Depletion by Infusion of a Humanized Anti-CCR4 Antibody, KW-0761, in Cancer Patients
20. Supplementary Figure 3 from Prolongation of Overall Survival in Advanced Lung Adenocarcinoma Patients with the XAGE1 (GAGED2a) Antibody
21. Supplementary Table 1 - 2 from Prolongation of Overall Survival in Advanced Lung Adenocarcinoma Patients with the XAGE1 (GAGED2a) Antibody
22. Supplementary Figure 4 from Prolongation of Overall Survival in Advanced Lung Adenocarcinoma Patients with the XAGE1 (GAGED2a) Antibody
23. Increase in Activated Treg in TIL in Lung Cancer and In Vitro Depletion of Treg by ADCC Using an Antihuman CCR4 mAb (KM2760)
24. Possible Role of IL-25 in Eosinophilic Lung Inflammation in Patients with Chronic Eosinophilic Pneumonia
25. Phase Ib study on the humanized anti-CCR4 antibody, KW-0761, in advanced solid tumors
26. Abstract A61: Development of automated immunoassay to detect serum biomarkers predicting response to immune checkpoint inhibitors in NSCLC
27. Predictive value of serum high‐mobility group box 1 levels for checkpoint inhibitor pneumonitis
28. Chapter Four - Immune checkpoint therapy and response biomarkers in non-small-cell lung cancer: Serum NY-ESO-1 and XAGE1 antibody as predictive and monitoring markers
29. TLR4 and NLRP3 inflammasome activation in monocytes by N-propionyl cysteaminylphenol-maleimide-dextran (NPCMD)
30. Production of NY-ESO-1 peptide/DRB1*08:03 tetramers and ex vivo detection of CD4 T-cell responses in vaccinated cancer patients
31. Drug fever after cancer chemotherapy is most commonly observed on posttreatment days 3 and 4
32. Increased Galectin-9 concentration and number of CD4+Foxp3high+Cells in bronchoalveolar lavage fluid of patients with cryptogenic organizing pneumonia
33. Predictive value of serum high‐mobility group box 1 levels for checkpoint inhibitor pneumonitis.
34. Phase I and II Trials of Vinorelbine With Carboplatin for Patients 75 Years of Age or Older With Previously Untreated Non–Small-Cell Lung Cancer
35. Relationship between clinical efficacy for pulmonary MAC and drug-sensitivity test for isolated MAC in a recent 6-year period
36. Randomized Phase II Trial of Irinotecan with Paclitaxel or Gemcitabine for Non-small Cell Lung Cancer: Association of UGT1A1*6 and UGT1A1*27 with Severe Neutropenia
37. Stability of sealed-bag samples for off-line measurement of fractional exhaled nitric oxide
38. Pharmacokinetics of Gefitinib Predicts Antitumor Activity for Advanced Non-small Cell Lung Cancer
39. Clinical usefulness of combination chemotherapy for pulmonary Mycobacterium avium complex disease
40. Tumor PD-L1 and VEGF Expression, and CD8 T Cell Infiltration Predict Clinical Response to Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer
41. A Phase I Study of Amrubicin and Carboplatin for Previously Untreated Patients with Extensive-Disease Small Cell Lung Cancer
42. Clinical evaluation of QuantiFERON TB-2G test in patients with healed pulmonary tuberculosis
43. Transitional changes in T-cell responses to Mycobacterium tuberculosis-specific antigens during treatment
44. Induction of Heat Shock Protein Closely Correlates with Protection Against Toxoplasma gondii Infection
45. Critical role of interleukin-5 in the development of a mite antigen-induced chronic bronchial asthma model
46. Phase II study of irinotecan and cisplatin with concurrent split-course radiotherapy in limited-disease small cell lung cancer
47. Impaired coronary flow reserve in obstructive sleep apnea and its improvement after continuous positive airway pressure therapy: a transthoracic Doppler echocardiographic study
48. Community-acquired macrolide-resistant Mycoplasma pneumoniae pneumonia in patients more than 18 years of age
49. Clinical Utility of the QuantiFERON TB-2G Test for Elderly Patients With Active Tuberculosis
50. Induction Chemotherapy with Cisplatin, Vinorelbine, and Mitomycin-C Followed by Surgery for Patients with Pathologic N2 Non–Small-Cell Lung Cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.